Neonc Technologies (NASDAQ:NTHI) Lowered to “Sell” Rating by Wall Street Zen

Wall Street Zen downgraded shares of Neonc Technologies (NASDAQ:NTHI) from a hold rating to a sell rating in a research report report published on Saturday morning.

Several other equities analysts also recently weighed in on NTHI. BTIG Research restated a “buy” rating and set a $15.00 price target on shares of Neonc Technologies in a report on Tuesday, May 26th. Maxim Group started coverage on shares of Neonc Technologies in a research note on Monday, May 18th. They issued a “buy” rating and a $20.00 price target on the stock. Weiss Ratings downgraded shares of Neonc Technologies from a “sell (d-)” rating to a “sell (e+)” rating in a research report on Wednesday, June 24th. Finally, Alliance Global Partners initiated coverage on shares of Neonc Technologies in a research note on Tuesday, May 19th. They set a “buy” rating and a $13.00 price objective for the company. Three equities research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat, Neonc Technologies has a consensus rating of “Hold” and a consensus price target of $16.00.

Neonc Technologies Stock Performance

Neonc Technologies stock opened at $4.22 on Friday. Neonc Technologies has a twelve month low of $3.01 and a twelve month high of $12.99. The stock’s 50 day moving average is $4.11 and its 200 day moving average is $6.10.

Neonc Technologies (NASDAQ:NTHI) last announced its quarterly earnings data on Friday, August 14th. The company reported ($0.58) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.12) by ($0.46).

Hedge Funds Weigh In On Neonc Technologies

Hedge funds have recently bought and sold shares of the business. Barclays PLC grew its stake in shares of Neonc Technologies by 5,314.8% in the fourth quarter. Barclays PLC now owns 9,151 shares of the company’s stock worth $76,000 after acquiring an additional 8,982 shares during the period. Goldman Sachs Group Inc. bought a new position in Neonc Technologies during the fourth quarter valued at approximately $124,000. Global Retirement Partners LLC bought a new position in Neonc Technologies during the second quarter valued at approximately $126,000. OMERS ADMINISTRATION Corp purchased a new stake in Neonc Technologies in the fourth quarter worth approximately $126,000. Finally, Royal Bank of Canada purchased a new stake in Neonc Technologies in the first quarter worth approximately $247,000.

About Neonc Technologies

Neonc Technologies Holdings, Inc develops novel molecular technology that provides enhanced targeted delivery of technologies for treating central nervous system diseases. Its lead products in development include NEO100, which is in Phase 2a clinical trials for treating glioblastoma; and NEO212, a covalently conjugated molecule combining the chemotherapeutic drug temozolomide with perillyl alcohol that is completed preclinical testing. The company was incorporated in 2023 and is based in Los Angeles, California.